In a phase II trial (PETRARCA, NCT02581462) FLOT in combination with trastuzumab and pertuzumab was associated with high rates of PCR and node negativity in HER2-positive esophagogastric adenocarcinoma [25]. This evidence concerns the gene ERBB2 and gastroesophageal junction adenocarcinoma.